 Rowley Law PLLC is investigating potential securities law violations by Cellular Biomedicine Group, Inc. NASDAQ: CBMG and its board of directors concerning the proposed acquisition of the company by members of Cellular Biomedicine Groups senior management and other investors. Stockholders will receive 19.75 in cash for each share of Cellular Biomedicine Group stock that they hold. The transaction is expected to close in the fourth quarter of 2020. 